OMTX-705 is under clinical development by Oncomatryx Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of ...

How to Implement an Effective Cleanroom Monitoring System In light of these potential problems, biopharma companies should ...

FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...